研究疾病:
|
缺血性脑卒中
|
研究疾病代码:
|
|
Target disease:
|
Acute ischemic stroke
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
治疗新技术临床试验
New Treatment Measure Clinical Study
|
研究目的:
|
论证时空针灸纳甲法早期干预缺血性脑卒中的有效性和安全性,进一步阐明时空针灸纳甲法对缺血性脑卒中的作用机制,为临床上治疗缺血性脑卒中提供新思路及客观的临床研究资料。
|
Objectives of Study:
|
To demonstrate the effectiveness and safety of Time-Acupoints-Space acupuncture Najia method in early intervention of acute ischemic stroke, further clarify the mechanism of Time-Acupoints-Space acupuncture Najia method on acute ischemic stroke, and provide new ideas and objective clinical research data for clinical treatment of acute ischemic stroke.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
(1)符合脑梗死的中、西医诊断标准;
(2)首次单侧发病,缺血性脑卒中2周内;
(3)年龄18~75周岁;
(4)病情稳定,意识清晰,格拉斯哥昏迷评分量表(Glasgow Coma Scale, GCS)≥13分;
(5)神经功能缺损的严重程度:美国国立卫生研究院脑卒中量表(National Institutes of Health Stroke Scale, NIHSS)≥4分
(6)入院前无严重残疾:MRS评分量表(Modified Rankin Scale, MRS)≤3分;
(7)无严重失语症或有失语症但不影响交流和完成指令性动作(失语症严重程度分级2级以上);
(8)第一次采血前1周内未用激素及胃肠动力药;
(9)同意并签署知情同意书。
|
Inclusion criteria
|
(1) Meet the diagnostic criteria of Chinese and Western medicine for acute ischemic stroke;
(2) First unilateral onset, within 2 weeks of acute ischemic stroke;
(3) Age 18 ~ 75 years old;
(4) Stable condition, clear consciousness, Glasgow Coma Scale (GCS) ≥ 13 points;
(5) Severity of neurological deficit: National Institutes of Health Stroke Scale (NIHSS) ≥ 4 points
(6) No serious disability before admission: Mrs score scale (modified Rankin scale, MRS) ≤ 3 points;
(7) No severe aphasia or aphasia, but it does not affect communication and completion of mandatory actions (the severity of aphasia is above grade 2);
(8) No hormone and gastrointestinal motility drugs were used within 1 week before the first blood collection;
(9) Agree and sign the informed consent form.
|
排除标准:
|
(1)短暂性脑缺血发作(TIA)、脑出血、蛛网膜下腔出血患者;
(2)中风病中脏腑者;
(3)既往有消化道、心血管、肿瘤、造血系统等其他严重疾病经治疗未控制的患者;
(4)此次发病存在应激性溃疡出血,或发病后发生严重的消化道出血患者;
(5)有失语、重度认知障碍及精神类疾病等无法配合信息采集患者;
(6)有严重并发症者,如心肺功能不全、肝肾功能不全、癌症、痴呆等,或者合并有疾病或残疾如类风湿关节炎、痛风、截肢等临床事件而影响本病的疗效评价者;
(7)对针刺惧怕,或针刺有皮肤病患者;
(8)目前正在参加其他临床研究,可能干扰本试验结果者。
|
Exclusion criteria:
|
(1) Patients with transient ischemic attack (TIA), intracerebral hemorrhage and subarachnoid hemorrhage;
(2) Those with viscera in stroke;
(3) Patients with other serious diseases such as digestive tract, cardiovascular system, tumor and hematopoietic system that have not been controlled after treatment;
(4) Patients with stress ulcer bleeding or severe gastrointestinal bleeding after the onset of the disease;
(5) Patients with aphasia, severe cognitive impairment and mental diseases who cannot cooperate with information collection;
(6) Those with serious complications, such as cardiopulmonary insufficiency, liver and kidney insufficiency, cancer, dementia, etc., or combined with diseases or disabilities, such as rheumatoid arthritis, gout, amputation and other clinical events that affect the efficacy evaluation of the disease;
(7) Fear of acupuncture, or patients with skin diseases caused by acupuncture;
(8) Those who are currently participating in other clinical studies and may interfere with the results of this trial.
|
研究实施时间:
Study execute time:
|
从From
2022-05-01
至To
2022-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2022-05-15
至To
2022-12-31
|